Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Drug side effects

FDA strengthens fluoroquinolone warnings

Revised warnings about the risks of being left permanently disabled after taking fluoroquinolone antibiotics have been added to products in the United States following a safety review by the US Food and Drug Administration (FDA).

The FDA carried out a review and found that both oral and injectable fluoroquinolones are associated with potentially lifelong disabling side effects involving tendons, muscles, joints, nerves and the central nervous system. The effects can appear weeks after taking the antibiotics.

The agency has subsequently decided that fluoroquinolones should be reserved for serious bacterial infections, including anthrax, plague and bacterial pneumonia where their benefits outweigh the risks.

For patients with acute bacterial sinusitis, acute exacerbation of chronic bronchitis and uncomplicated urinary tract infections, fluoroquinolones should only be used when there are no alternative treatment options, the FDA says.

The boxed warnings that appear on the packets of fluoroquinolone medicines have been updated by the FDA, drawing attention to the risk of disability and the new prescribing restrictions for specific patients. This information also appears in a patient medication guide, which must be given out with each fluoroquinolone prescription.

The new safety advice about fluoroquinolones is the latest by the FDA which first warned about the risks associated with this class of antibiotics in 2008.

In the United States, FDA-approved fluoroquinolones include levofloxacin, ciprofloxacin, ciprofloxacin extended-release tablets, moxifloxacin, ofloxacin and gemifloxacin.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2016.20201508

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.


Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Fluoroquinolone antibiotic molecule

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.